tiprankstipranks
Trending News
More News >
Philogen SpA (IT:PHIL)
:PHIL

Philogen SpA (PHIL) AI Stock Analysis

Compare
7 Followers

Top Page

IT

Philogen SpA

(Stuttgart:PHIL)

Rating:73Outperform
Price Target:
€25.00
▲(11.11%Upside)
Philogen SpA's strong financial performance, highlighted by significant revenue and margin improvements, positively impacts its overall score. While the technical analysis suggests stable price trends, the fair valuation indicates potential for growth. Absence of earnings call and dividend yield slightly dampens enthusiasm, but the company's solid financial health positions it well for the future.
Positive Factors
Clinical Trials
Philogen has completed recruitment for its EU Phase 3 trial of Fibromun in soft tissue sarcoma, which is a significant milestone for the company.
Financial Growth
Philogen expects to triple its revenues as a result of the partnership agreement with Sun Pharma, highlighting strong financial growth prospects.
Partnerships
Philogen has extended its partnership with Sun Pharma to include Fibromun, enhancing its global commercialization prospects.
Negative Factors
Dividend Yield
The dividend yield is expected to remain at 0.0%, which might be a concern for investors seeking income from dividends.

Philogen SpA (PHIL) vs. iShares MSCI Italy ETF (EWI)

Philogen SpA Business Overview & Revenue Model

Company DescriptionPhilogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase I clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.
How the Company Makes MoneyPhilogen SpA generates revenue primarily through the development and commercialization of its pharmaceutical products. The company engages in partnerships and collaborations with other pharmaceutical and biotechnology firms to advance its clinical programs and to co-develop therapeutics. These partnerships often include licensing agreements, milestone payments, and royalties based on sales of co-developed products. Additionally, Philogen may receive funding from grants and research collaborations, contributing to its revenue streams. The company's earnings are largely driven by the successful development and market approval of its therapeutic candidates.

Philogen SpA Financial Statement Overview

Summary
Philogen SpA demonstrates excellent financial performance in 2024, with strong revenue growth and margin improvements. The company turned profitable with a net profit margin of 58.3%, and the balance sheet is debt-free with a robust equity base. Cash flows are positive and well-managed, supporting operational and investment activities.
Income Statement
85
Very Positive
Philogen SpA shows strong revenue growth with a significant increase from €23.1M in 2023 to €77.6M in 2024. The gross profit margin improved drastically from 24.5% in 2023 to 53.6% in 2024. The company turned profitable with a net profit margin of 58.3% in 2024, a remarkable recovery from previous losses. EBIT and EBITDA margins also improved to 53.6% in 2024, reflecting efficient cost management.
Balance Sheet
78
Positive
The balance sheet is strong with no debt in 2024, improving the debt-to-equity ratio to 0. The equity ratio is robust at 88.4%, indicating a solid equity base. However, the total assets increased less significantly compared to equity, which may limit leverage opportunities.
Cash Flow
80
Positive
Philogen's free cash flow turned positive in 2024, with a substantial increase to €38.7M from a negative position in 2023. The operating cash flow to net income ratio is 0.90, indicating efficient cash generation relative to net earnings. The free cash flow to net income ratio is 0.85, showing strong cash flow management.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
74.00M23.13M23.71M2.50M4.78M
Gross Profit
54.42M5.67M10.53M-8.14M-5.05M
EBIT
37.73M-8.84M240.00K-16.77M-12.13M
EBITDA
44.75M-2.05M-1.19M-12.98M-10.53M
Net Income Common Stockholders
45.29M-6.16M-5.38M-15.72M-13.29M
Balance SheetCash, Cash Equivalents and Short-Term Investments
113.73M75.34M86.20M101.68M61.94M
Total Assets
168.45M119.27M125.83M132.75M85.47M
Total Debt
11.51M14.91M11.89M11.84M11.98M
Net Debt
-19.07M-720.00K-12.54M2.96M23.00K
Total Liabilities
29.80M28.68M27.91M27.67M29.80M
Stockholders Equity
138.66M90.59M97.92M105.09M55.67M
Cash FlowFree Cash Flow
38.67M-10.69M-9.15M-25.85M-16.81M
Operating Cash Flow
40.84M-4.82M-4.94M-19.03M-13.16M
Investing Cash Flow
-22.28M159.00K24.20M-47.77M17.77M
Financing Cash Flow
-3.78M-4.17M-3.78M63.05M3.79M

Philogen SpA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price22.50
Price Trends
50DMA
21.52
Positive
100DMA
20.01
Positive
200DMA
19.94
Positive
Market Momentum
MACD
0.26
Positive
RSI
56.37
Neutral
STOCH
35.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHIL, the sentiment is Positive. The current price of 22.5 is below the 20-day moving average (MA) of 22.59, above the 50-day MA of 21.52, and above the 200-day MA of 19.94, indicating a neutral trend. The MACD of 0.26 indicates Positive momentum. The RSI at 56.37 is Neutral, neither overbought nor oversold. The STOCH value of 35.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:PHIL.

Philogen SpA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
€660.89M20.0239.51%219.91%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
€1.68B7.9630.06%11.78%
€5.04B27.3611.27%1.30%
€40.63B16.004.83%7.49%
€1.81B43.3014.13%0.25%
€16.80B23.9615.32%1.37%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IT:PHIL
Philogen SpA
22.50
1.70
8.17%
GB:0RON
BFF Bank SpA
9.01
-0.06
-0.66%
GB:0GZX
DiaSorin S.p.A.
93.90
-4.70
-4.77%
GB:0N9S
ENI S.p.A.
13.35
0.22
1.68%
GB:0O2B
Gruppo Mutuionline SpA
48.13
13.49
38.94%
GB:0NUX
Prysmian SpA
58.08
1.24
2.18%

Philogen SpA Corporate Events

Philogen Updates on Share Buyback Program
Jun 3, 2025

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 790 shares at an average price of Euro 22.50 per share, totaling Euro 17,775.00. Since the program’s inception, the company has acquired 14,742 shares, representing 0.0363% of its share capital, which may impact its market positioning and shareholder value.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Releases Shareholders’ Meeting Minutes
May 26, 2025

Philogen S.p.A. has made available the minutes of its Shareholders’ Meeting held on April 29, 2025. This announcement underscores the company’s commitment to transparency and governance, potentially reinforcing stakeholder confidence and supporting its strategic objectives in the biotechnology sector.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Updates on Share Buyback Program
May 26, 2025

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 1,800 shares between May 19 and May 23, 2025, at an average price of Euro 22.30 per share, totaling Euro 40,140.00. Since the program’s inception, the company has acquired 13,952 shares, representing 0.0344% of its share capital, with a total value of Euro 309,433.85. This move is part of Philogen’s strategy to manage its capital structure and potentially increase shareholder value, reflecting confidence in its ongoing operations and future prospects.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen Updates Share Buyback Program with Recent Purchases
May 19, 2025

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 7,628 shares between May 12 and May 16, 2025, at an average price of Euro 22.3742 per share, totaling Euro 170,670.65. This move is part of a broader strategy to enhance shareholder value and demonstrates the company’s commitment to its investors. The buyback program, since its inception, has seen the acquisition of 12,152 shares, representing 0.0299% of the share capital, indicating Philogen’s proactive approach in managing its equity and reinforcing its market position.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Updates on Share Buyback Program
May 12, 2025

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 4,524 shares from May 7 to May 9, 2025, representing 0.0111% of its share capital at an average price of Euro 21.80 per share. This move is part of a broader strategy approved by the Board of Directors and Shareholders’ Meeting, reflecting the company’s commitment to enhancing shareholder value. As of May 9, 2025, Philogen holds a total of 336,674 ordinary shares, equating to 0.8290% of its share capital, indicating a strategic approach to managing its equity and potentially impacting its market positioning.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

Philogen S.p.A. Reports Strong Financial Position and Progress in Clinical Trials
May 6, 2025

Philogen S.p.A. reported a positive net financial position of €93.574 million for the first quarter of 2025, despite a decrease from the previous quarter. The company is progressing with its main trials, Nidlegy™ and Fibromun, and has initiated a share buyback program. The Board of Directors has also reconstituted key committees and noted significant advancements in their industrial programs. These developments reflect Philogen’s strategic focus on expanding its clinical pipeline and maintaining financial stability, which could enhance its position in the biopharmaceutical industry.

Philogen S.p.A. Approves 2024 Financials and Appoints New Board
Apr 29, 2025

Philogen S.p.A.’s Shareholders’ Meeting approved the 2024 financial statements, allocating a net profit of over 45 million euros to reserves. The meeting also appointed a new Board of Directors, with Dr. Duccio Neri as Chairman, and approved amendments to incentive plans for employees and directors, including a stock grant plan and a shareholding plan.

Philogen S.p.A. Advances Share Buyback Program with Latest Acquisition
Apr 14, 2025

Philogen S.p.A. announced the purchase of 6,120 of its own shares as part of its ongoing share buyback program, approved by the Board of Directors in December 2024. This transaction, conducted on the Euronext Milan market, represents 0.0151% of the company’s share capital. Since the start of the buyback program, Philogen has acquired a total of 55,776 shares, equivalent to 0.1373% of its share capital, reflecting a strategic move to consolidate its market position and potentially enhance shareholder value.

Philogen Announces Voting Rights Ahead of Shareholders’ Meeting
Apr 11, 2025

Philogen S.p.A. has announced the total amount of voting rights ahead of its upcoming Shareholders’ Meeting. The company disclosed that its share capital consists of 40,611,111 shares, translating to 63,347,611 voting rights. This announcement underscores Philogen’s commitment to transparency and provides stakeholders with crucial information about its governance structure, potentially impacting investor confidence and market perception.

Philogen S.p.A. Proposes New Board of Directors
Apr 7, 2025

Philogen S.p.A. has announced the submission of a list of candidates for the appointment of its Board of Directors, which will be decided at the upcoming shareholders’ meeting. The list, presented by major shareholder Nerbio S.r.l., includes ten candidates, with Dr. Duccio Neri proposed as Chairman. This move is part of the company’s adherence to regulatory and statutory provisions, ensuring compliance with governance codes, and aims to solidify its leadership structure.

Philogen Updates on Share Buyback Program
Apr 7, 2025

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 8,199 shares, representing 0.0202% of its share capital, for a total of Euro 162,240.01 between March 31 and April 4, 2025. This move is part of a broader strategy to manage its capital structure, with the company having acquired a total of 49,656 shares since the program’s inception. The buyback program reflects Philogen’s commitment to enhancing shareholder value and optimizing its financial resources.

Philogen Updates Share Buyback Program, Strengthening Market Position
Mar 31, 2025

Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 6,473 shares between March 24 and March 28, 2025, at an average price of Euro 19.4810 per share, totaling Euro 126,100.61. This move is part of a broader strategy to manage capital structure, with the company having acquired a total of 41,457 shares since the program’s inception. The buyback program reflects Philogen’s confidence in its market positioning and aims to enhance shareholder value.

Philogen Publishes Shareholders’ Meeting Documentation for April 2025
Mar 28, 2025

Philogen S.p.A. has released documentation related to its upcoming shareholders’ meeting on April 29, 2025. The documents include explanatory reports on various agenda items such as financial statements, remuneration policy, incentive plans, and proposals for share capital increase. These documents are available on the company’s website and through authorized storage mechanisms. The announcement highlights Philogen’s ongoing efforts to engage with shareholders and manage its financial and strategic planning, potentially impacting its market position and stakeholder interests.

Philogen S.p.A. Achieves Record Profits and Advances Cancer Therapy Pipeline
Mar 27, 2025

Philogen S.p.A. reported a significant financial turnaround in 2024, achieving record profits with revenues tripling from the previous year. The company is advancing its product pipeline with key developments including the ongoing evaluation of Nidlegy™ for melanoma by EMA, promising results in radiopharmaceuticals, and a new collaboration with Sun Pharma for Fibromun. These advancements underscore Philogen’s strengthened position in the biotechnology sector and its commitment to innovative cancer treatments.

Philogen S.p.A. Announces Shareholder Meeting to Discuss Financial and Governance Strategies
Mar 18, 2025

Philogen S.p.A. has announced a meeting for its shareholders to discuss and resolve various financial and governance matters. The agenda includes approval of financial statements, remuneration policies, and the appointment of a new Board of Directors. Additionally, the meeting will address amendments to incentive plans and authorize the purchase and disposal of own shares, reflecting the company’s strategic focus on enhancing shareholder value and aligning management incentives.

Philogen S.p.A. Updates on Share Buyback Program
Mar 17, 2025

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 1,887 shares between March 10 and March 14, 2025, at an average price of Euro 18.6538 per share, totaling Euro 35,199.73. This move is part of a broader strategy, with the company having acquired 34,984 shares since the program’s inception, reflecting its commitment to enhancing shareholder value and potentially signaling confidence in its market position.

Philogen Updates Share Buyback Program with Recent Purchases
Mar 10, 2025

Philogen S.p.A. has updated its share buyback program, purchasing 3,872 shares from March 3 to March 7, 2025, representing 0.0095% of its share capital at an average price of Euro 18.6767 per share. This move is part of a broader strategy, with the company having acquired a total of 33,097 shares since the program’s inception, amounting to 0.0815% of its share capital. The buyback program is indicative of Philogen’s efforts to enhance shareholder value and maintain a strong market position in the biotechnology sector.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.